Core Viewpoint - The company emphasizes the accuracy and completeness of its financial disclosures and reports, ensuring no misleading statements or significant omissions are present [1][2][9]. Financial Data - The company has not made any retrospective adjustments or restatements to previous accounting data [3]. - As of September 30, 2025, the company repurchased 13,729,618 shares, representing 2.68% of its total share capital, with a total expenditure of approximately RMB 101.19 million [5]. Board Meeting - The sixth board meeting was held on October 23, 2025, with all six directors present, and the meeting complied with relevant legal and regulatory requirements [10]. - The board approved the third-quarter report for 2025, which had been reviewed and agreed upon by the audit committee [11][12].

Core Viewpoint - The pharmaceutical and biotechnology industry is showing strong performance in Q3, with several companies reporting significant year-on-year growth in net profit, particularly in the traditional Chinese medicine sector and contract research organizations (CROs) [1][2][6]. Group 1: Company Performance - Special One Pharmaceutical reported a net profit growth of 985.18% year-on-year for the first three quarters, with revenue reaching 692 million yuan, a 51.86% increase [2]. - WoHua Pharmaceutical achieved a net profit growth of 179.34%, with revenue of 625 million yuan, reflecting an 8.31% increase [2]. - Other companies like LiSheng Pharmaceutical and Guangzheng Ophthalmology also reported net profit growth exceeding 100% [1]. Group 2: Industry Trends - The CRO and CDMO sectors are expected to continue their positive performance from the first half of the year, with strong demand anticipated [1][6]. - The Chinese medicine, medical device, raw material drug, and pharmacy sectors are also showing promising results, with several companies reporting substantial growth [1][6]. - The market is shifting towards innovative drugs, with a focus on companies that are experiencing turning points in their performance [6][7]. Group 3: Market Outlook - Companies like Mindray Medical expect revenue growth in the international market to accelerate, supported by ongoing localization efforts [4]. - The demand for CDMO services is optimistic, with increased capacity utilization and a rise in new client projects [5]. - Analysts suggest that the innovative drug sector will remain a key investment focus, with expectations of continued high revenue growth and improved profitability [6][7].

Core Viewpoint - The company emphasizes the accuracy and completeness of its financial disclosures and reports, ensuring no misleading statements or significant omissions are present [2][9]. Financial Data Summary - The third-quarter financial report has not been audited [3][8]. - The company has not made any retrospective adjustments or restatements to previous accounting data [3]. - Non-recurring gains and losses are not applicable, and there are no other items classified as non-recurring [3]. Shareholder Information - As of September 30, 2025, the company repurchased 13,729,618 shares, accounting for 2.68% of the total share capital, with a total expenditure of approximately RMB 101.19 million [5]. - The highest repurchase price was RMB 8.03 per share, and the lowest was RMB 6.79 per share [5]. Board Meeting Details - The sixth board meeting was held on October 23, 2025, with all six directors present, and the meeting complied with relevant laws and regulations [10]. - The board approved the third-quarter report during the meeting, which had been reviewed and agreed upon by the audit committee [11][12].

Core Insights - The company reported significant growth in revenue and net profit for the first three quarters of 2025, with revenue reaching 692 million yuan, a year-on-year increase of 51.86%, and net profit at 65.22 million yuan, up 985.18% [1] - The growth is primarily attributed to a notable increase in sales of traditional Chinese medicine products [1] Financial Performance - In Q3 2025, the company achieved revenue of 201 million yuan, reflecting a year-on-year growth of 41.49%, while net profit for the quarter was 27.21 million yuan, an increase of 719.47% [1] - The company's core product, "Te Yi" cough tablets, sold 331 million pieces in the first half of 2025, recovering to 61.29% of the sales volume compared to the same period in 2023 [2] Marketing and Organizational Changes - The company has completed a comprehensive upgrade of its marketing organizational structure, creating new departments such as self-operated sales, online marketing, third-party sales, brand marketing, and market supervision [2] - The restructuring has led to an increase of over 100 frontline sales personnel, with plans to continue recruiting based on market development needs [2] - The company aims to enhance the market development of potential traditional Chinese medicine products and strengthen its multi-product tier strategy [2]

（文章来源：证券日报） 证券日报网讯 10月23日晚间，特一药业发布2025年第三季度报告称，2025年第三季度公司实现营业收 入200，707，722.19元，同比增长41.49%；归属于上市公司股东的净利润为27，209，399.91元，同比 增长719.47%。 ...

Major Events - Former Chairman of Beiyin Wealth Management, Fang Yi, has joined Huaxia Bank as Chief Risk Officer, pending regulatory approval [4] - Xilai Materials' subsidiary plans to invest 2 billion yuan in a semiconductor core component project, expected to generate over 1.5 billion yuan in annual output after reaching production [5][6] - Huatai Securities' subsidiary Huatai Futures has appointed Zhao Changtao as the new chairman [7] - Chuanfa Longmang's subsidiary plans to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project [8] - Huagong Technology is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] - Jiangsu Leili's actual controller has changed from Su Jianguo to both Su Jianguo and Su Da due to internal share transfers [10] - Electric Power Investment Energy has been unable to contact independent director Han Fang, but this does not affect the board's operation [11] - Qiaqia Food's subsidiary is establishing an investment company focused on the leisure food industry with a total investment of 4 billion yuan [12][13] - Steel Research High-tech plans to set up a wholly-owned subsidiary in Saudi Arabia with an investment of up to 138 million yuan [14] - Yangjie Technology has terminated the acquisition of 100% equity in Better Electronics due to differences in business types and management [15] Performance Reports - Youfa Group reported a 2320.53% increase in net profit for Q3, despite a 3.97% decline in revenue [16] - Zhuoyi Information's net profit increased by 2074.65% in Q3, with revenue growth of 2.52% [17] - North Navigation's Q3 net profit surged by 1681.27%, with a 52.12% increase in revenue [18] - Tianneng Heavy Industry's net profit grew by 1359.03% in Q3, driven by increased sales of tower tubes [19] - Te Yi Pharmaceutical's net profit rose by 985.18% in Q3, with significant growth in traditional Chinese medicine sales [20] - Hualgreen Bio's Q3 net profit increased by 619.37%, with a 35.24% rise in revenue [21] - Zhenlei Technology's net profit grew by 598.09% in Q3, supported by strong revenue growth [22] - Shengyi Electronics expects a net profit increase of 476% to 519% for the first three quarters of 2025 [23] - Glodon reported a 244.89% increase in Q3 net profit, despite a slight decline in revenue [24] - Yingli Co., Ltd. saw a 229.14% increase in Q3 net profit, with a 14.73% rise in revenue [25] - Guangkang Biochemical's Q3 net profit increased by 236.87%, despite a decline in revenue [26] - High-speed Electric's Q3 net profit rose by 242.35%, with a 44.51% increase in revenue [27] - Wide Special Materials reported a 213.65% increase in net profit for Q3, driven by improved gross margins [28] - Baofeng Energy's Q3 net profit increased by 162.34%, attributed to increased production capacity [29] - Sanfu Co., Ltd. reported a 162.25% increase in Q3 net profit, driven by improved profitability of potassium and silane products [30] - Wuku New Energy's Q3 net profit increased by 106.31%, despite a loss in the first three quarters [32] - Pioneering Technology's Q3 net profit grew by 94.01%, supported by a recovery in the household energy storage market [33] - Sanlife Guojian's net profit increased by 71.15% in Q3, driven by project collaboration and CDMO business growth [34] - BGI Genomics reported a loss of 120 million yuan in the first three quarters, despite revenue growth [35] - Rejing Bio reported a net loss of 10.9 million yuan in the first three quarters, impacted by industry policies [36] - Jiangshan Oupai reported a net loss of 51.58 million yuan in Q3, attributed to market downturns and increased competition [38] - Taiping Bird reported a net loss of 49.45 million yuan in Q3, due to declining revenue and increased inventory losses [39] - Zhongke Tongda reported a loss of 6.87 million yuan in the first three quarters, affected by project delays and market competition [40] - Wolong New Energy reported a loss of 579.7 thousand yuan in Q3, transitioning from profit to loss [41] Major Contracts - Jinggong Steel Structure signed a significant overseas project contract worth approximately 1.23 billion yuan [42][43] - New Beiyang's subsidiary won a 105 million yuan postal equipment outsourcing project [44] - Maipu Medical plans to sign product sales agency agreements with related parties, with estimated procurement amounts of 21.5 million yuan and 3.5 million yuan [45] Shareholding Changes - Yunlu Co., Ltd. shareholder Guo Keyun plans to reduce his stake by up to 3% [46] Financing - Xinda Securities has received approval from the CSRC to issue up to 10 billion yuan in technology innovation corporate bonds [47]

Group 1 - HuanGong Technology plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [1] - XinLai YingCai's subsidiary plans to invest 2 billion yuan in a semiconductor core component project, aiming for an annual output value exceeding 1.5 billion yuan [2] - ChuanFa LongMang's subsidiary intends to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project to strengthen its new energy materials business [4] Group 2 - YouFa Group reported a net profit increase of 2320.53% in Q3, with a revenue of 13.104 billion yuan, down 3.97% year-on-year [6] - ZhuoYi Information's Q3 net profit rose by 2074.65%, with revenues of 88.8168 million yuan, up 2.52% year-on-year [5] - BeiFang Navigation's Q3 net profit increased by 1681.27%, with revenues of 765 million yuan, up 52.12% year-on-year [6] Group 3 - TianNeng Heavy Industry reported a Q3 net profit growth of 1359.03%, with revenues of 1.055 billion yuan, up 59.33% year-on-year [7][8] - TeYi Pharmaceutical's Q3 net profit increased by 985.18%, with revenues of 201 million yuan, up 41.49% year-on-year [9] - HuaLv Biological's Q3 net profit grew by 619.37%, with revenues of 369 million yuan, up 35.24% year-on-year [10] Group 4 - ShengYi Electronics expects a net profit increase of 476% to 519% for the first three quarters, with revenues projected between 6.614 billion yuan and 7.034 billion yuan [12] - YingLi Co., Ltd. reported a Q3 net profit increase of 229.14%, with revenues of 581 million yuan, up 14.73% year-on-year [13] - GuangKang Biochemical's Q3 net profit increased by 236.87%, with revenues of 151 million yuan, down 9.41% year-on-year [14] Group 5 - High-speed Electric reported a Q3 net profit growth of 242.35%, with revenues of 277 million yuan, up 44.51% year-on-year [15] - Wide Special Materials reported a Q3 net profit increase of 213.65%, with revenues of 1.24 billion yuan, up 15.03% year-on-year [16] - BaoFeng Energy's Q3 net profit increased by 162.34%, with revenues of 12.725 billion yuan, up 72.49% year-on-year [17] Group 6 - Sanfu Co., Ltd. reported a Q3 net profit increase of 162.25%, with revenues of 540 million yuan, up 23.52% year-on-year [18] - WuKang New Energy's Q3 net profit increased by 106.31%, with revenues of 2.15 billion yuan, up 69.79% year-on-year [19] - PaiNeng Technology's Q3 net profit grew by 94.01%, with revenues of 863 million yuan, up 56.13% year-on-year [20] Group 7 - SanSheng GuoJian reported a Q3 net profit increase of 71.15%, with revenues of 474 million yuan, up 38.27% year-on-year [21] - ReJing Biological reported a net loss of 109 million yuan for the first three quarters, with revenues of 310 million yuan, down 19.8% year-on-year [22] - JiangShan OuPai reported a Q3 net loss of 51.58 million yuan, with revenues of 416 million yuan, down 48.92% year-on-year [23][24]

格隆汇10月23日丨特一药业(002728.SZ)公布2025年第三季度报告，营业收入为2.01亿元，同比上升 41.49%；归属于上市公司股东的净利润为2720.94万元，同比上升719.47%；归属于上市公司股东的扣除 非经常性损益的净利润为2472.44万元，同比上升1278.50%。 ...

Core Viewpoint - The company Te Yi Pharmaceutical (SZ 002728) announced the convening of its sixth board meeting to review the third quarter report for 2025, highlighting its financial performance and business structure [1]. Financial Performance - For the first half of 2025, Te Yi Pharmaceutical reported that its revenue composition was as follows: pharmaceutical manufacturing accounted for 98.52%, pharmaceutical commerce for 0.87%, and chemical products and others for 0.61% [1]. - As of the report date, the market capitalization of Te Yi Pharmaceutical was 5.5 billion yuan [1].

智通财经APP讯，特一药业(002728.SZ)发布2025年三季度报告，前三季度，公司实现营业收入6.92亿 元，同比增长51.86%。归属于上市公司股东的净利润6521.71万元，同比增长985.18%。归属于上市公司 股东的扣除非经常性损益的净利润6280.97万元，同比增长2508.06%。 ...